SERUM LEVEL OF DIPEPTIDYL PEPTIDASE-4 AS A POTENTIAL BIOMARKER FOR MEDULLARY THYROID CANCER

2018 ◽  
Vol 40 (4) ◽  
pp. 299-302
Author(s):  
R Abooshahab ◽  
E Niyazi ◽  
P Yaghmaie ◽  
H G Ghadaksaz ◽  
M Hedayati
Keyword(s):  
Insulin Resistance ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Serum Levels ◽  
Dipeptidyl Peptidase ◽  
Control Group ◽  
Medullary Thyroid ◽  
Dipeptidyl Peptidase 4 ◽  
Potential Biomarker ◽  
Significant Difference

Aim: Adipokines are the proteins secreted from adipose tissue and play an important role in the control of metabolism. Dipeptidyl peptidase-4 (DPP4) is a novel adipokine with different biological role. As indicated by various studies, serum levels of DPP4 had been associated with body mass index (BMI), insulin resistance, metabolic syndrome and malignancy. The aim of this study was to assess the serum levels of DPP4 in patients with medullary thyroid cancer (MTC) in comparison with these in the control group. Materials and Methods: This study was performed on 45 MTC patients (24 females and 21 males) and 45 healthy controls (21 females and 24 males). DPP4 and insulin serum levels were measured by ELISA, fasting glucose serum levels by enzymecalorimetric method and insulin resistance index (HOMA-IR) by calculation using relevant equation. BMI (kg/m2) was also calculated. Results: Our data did not demonstrate a significant difference between serum DPP4 levels in MTC and healthy group (41.06 ± 22.08 ng/ml vs 39.94 ± 20.77 ng/ml, p > 0.05). Additionally, no significant difference was found in serum insulin and HOMA-IR concentrations between MTC patients and the controls (p > 0.05). Conclusions: This study suggests that the fluctuation in the levels of DPP4 does not play an important role in prognosis, early detection and diagnosis of MTC. Furthermore, higher levels of DPP4 cannot be considered as a risk factor for MTC.

scholarly journals Role of Milk-Derived Opioid Peptides and Proline Dipeptidyl Peptidase-4 in Autism Spectrum Disorders

Nutrients ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 87 ◽  
Author(s):  
Beata Jarmołowska ◽  
Marta Bukało ◽  
Ewa Fiedorowicz ◽  
Anna Cieślińska ◽  
Natalia Karolina Kordulewska ◽  
...  
Keyword(s):  
Opioid Peptides ◽  
Mononuclear Cells ◽  
Bovine Milk ◽  
Dipeptidyl Peptidase ◽  
Autism Spectrum ◽  
Control Group ◽  
Healthy Children ◽  
Dipeptidyl Peptidase 4 ◽  
Significant Difference

Opioid peptides released during digestion of dietary proteins such as casein, were suggested to contribute to autism development, leading to the announcement of opioid excess hypothesis of autism. This paper examines role of enzyme proline dipeptidyl peptidase-4 (DPPIV; EC 3.4.14.5) and it is exogenous substrate, β-casomorphin-7 (BCM7) in autism etiology. Our study included measurements of DPPIV and BCM7 concentrations in serum and urine, which were analyzed with ELISA assays and activity of DPPIV was measured by colorimetric test. The effect of opioid peptides from hydrolysed bovine milk on DPPIV gene expression in peripheral blood mononuclear cells (PBMC) in autistic and healthy children was determined using the Real-Time PCR (Polymerase Chain Reaction) method. Our research included 51 healthy children and 86 children diagnosed with autism spectrum disorder (ASD, ICDF84). We determined that the concentration of BCM7 in serum was significantly, 1.6-fold, higher in the ASD group than in controls (p < 0.0001). Concentration of DPPIV was found to also be significantly higher in serum from ASD children compared to the control group (p < 0.01), while we did not notice significant difference in enzymatic activity of serum DPPIV between the two study groups. We confirmed correlation according to the gender between analyzed parameters. The inspiration for this study emanated from clinical experience of the daily diet role in relieving the symptoms of autism. Despite this, we have concluded that milk-derived opioid peptides and DPPIV are potentially factors in determining the pathogenesis of autism; conducted studies are still limited and require further research.

scholarly journals Biomarker-Based Risk Stratification for Previously Untreated Medullary Thyroid Cancer

2010 ◽  
Vol 95 (6) ◽  
pp. 2655-2663 ◽  
Author(s):  
Andreas Machens ◽  
Henning Dralle
Keyword(s):  
Thyroid Cancer ◽  
Lymph Node ◽  
Lymph Node Metastases ◽  
Medullary Thyroid Cancer ◽  
Serum Levels ◽  
Neck Surgery ◽  
Lateral Neck ◽  
Medullary Thyroid ◽  
Node Metastases ◽  
Extent Of Disease

Abstract Context: Preoperative neck ultrasonography may yield false-negative findings in more than one-third of medullary thyroid cancer (MTC) patients. If not cleared promptly, cervical lymph node metastases may emerge subsequently. Reoperations entail an excess risk of surgical morbidity and may be avoidable. Objective: This comprehensive investigation aimed to evaluate in a head-to-head comparison the clinical utility of pretherapeutic biomarker serum levels (basal calcitonin; stimulated calcitonin; carcinoembryonic antigen) for indicating extent of disease and providing biochemical stratification of pretherapeutic MTC risk. Design: This was a retrospective analysis. Setting: The setting was a tertiary referral center. Patients: Included were 300 consecutive patients with previously untreated MTC. Interventions: The intervention was compartment-oriented surgery. Main Outcome Measure: Stratified biomarker levels were correlated with histopathologic extent of disease. Results: Higher biomarker levels reflected larger primary tumors and more lymph node metastases. Stratified basal calcitonin serum levels correlated better (r = 0.59) with the number of lymph node metastases than carcinoembryonic antigen (r = 0.47) or pentagastrin-stimulated calcitonin (r = 0.40) levels. Lymph node metastases were present in the ipsilateral central and lateral neck, contralateral central neck, contralateral lateral neck, and upper mediastinum, respectively, beyond basal calcitonin thresholds of 20, 50, 200, and 500 pg/ml. Bilateral compartment-oriented neck surgery achieved biochemical cure in at least half the patients with pretherapeutic basal calcitonin levels of 1,000 pg/ml or less but not in patients with levels greater than 10,000 pg/ml. Conclusions: Most newly diagnosed MTC patients, i.e. those with pretherapeutic basal calcitonin levels greater than 200 pg/ml, may need bilateral compartment-oriented neck surgery to reduce the number of reoperations.

Clinical correlates of thrombodynamics in men with metabolic syndrome: the impact of insulin resistance

2016 ◽  
Vol 62 (5) ◽  
pp. 24-25
Author(s):  
Anastasya A. Baranova ◽  
Ilya G. Pochinka ◽  
Leonid G. Strongin ◽  
Ksenia N. Jurkova ◽  
Maya I. Dvornikova
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Serum Levels ◽  
Control Group ◽  
C Reactive Protein ◽  
Clinical Correlates ◽  
Insulin Resistant ◽  
Reactive Protein ◽  
Significant Difference ◽  
The Impact

Background. Hypercoagulation is one of the cardiovascular risk factors in patients with metabolic syndrome (MS). It results from various factors including hyperhomocysteinemia, endothelial dysfunction, non-enzymatic glycation of proteins etc.The aim of this study was to assess clinical correlates of thrombodynamics in insulin resistant and non insulin resistant men with metabolic syndrome.Methods. We investigated 79 patients with MS diagnosed in accordance with IDF criteria (2009). The main group consisted of 44 men with MS including insulin resistance. The control group consisted of 35 men with MS not including insulin resistance. In addition to routine clinical tests we performed thrombodynamics assay and measured serum levels of asymmetric dimethylarginine (ADMA) and homocysteine. Mann-Whitney U-test and Spearmen’s correlation coefficient (rs) were used for statistical analysis.Results. There was no significant difference between thrombodynamics parameters, ADMA and homocysteine levels between the two groups. In both groups thrombodynamics parameters had no correlations with body mass index, hemoglobin level, platelet count and serum ADMA level. In patients with insulin resistance clot density correlated positively with serum level of C-reactive protein (rs=0.621, p=0.007); average and initial rates of clot growth correlated positively with homocysteine level (rs=0.539, p=0.017, and rs=0.554, p=0.014, respectively). In patients with insulin resistance clot density and rates of clot growth were not interrelated with the above mentioned parameters.Conclusions. The results of the study suggest that insulin resistant men with MS are characterized by clinical correlates between thrombodynamics parameters, homocysteine and C-reactive protein levels while patients without insulin resistance have other, unestablished determinants of clot density and rates of clot growth.

scholarly journals Serum adiponectin and resistin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome

2011 ◽  
Vol 2 (6) ◽  
pp. 235-245 ◽  
Author(s):  
Bertha Pangaribuan ◽  
Irawan Yusuf ◽  
Muchtaruddin Mansyur ◽  
Andi Wijaya
Keyword(s):  
Insulin Resistance ◽  
Polycystic Ovary ◽  
Serum Levels ◽  
Serum Adiponectin ◽  
Control Group ◽  
Case Group ◽  
Obese Women ◽  
Significant Difference ◽  
Group A ◽  
Group B

Objective: The role of insulin resistance in polycystic ovary syndrome (PCOS) has been established. However the role of adiponectin and resistin in the relationship between insulin resistance as markers of obesity and PCOS has not been conclusive. This study aims to determine the influence of the serum levels of adiponectin and resistin on PCOS, and assess possible correlations with the hormonal and metabolic parameters of the syndrome and obesity. Methods: This study continued a case control study that had finished recruiting 24 subjects of reproductive women with PCOS as a case group, and 24 subjects of normal ovulatory reproductive women without hyperandrogenism as a control group. Further, only 18 subjects of the control group had a body mass index (BMI) <25 kg/m2 and were included the data analysis, whereas others were excluded. Therefore, these study data were divided into three groups. Twenty-four PCOS patients from the case group were allocated to two groups, A ( n = 14) patients had PCOS + BMI ≥25 kg/m2; B ( n = 10) patients had PCOS + BMI <25 kg/m2. Group C was the control group of 18 reproductive women without PCOS + BMI <25 kg/m2. Blood samples were collected between day 3 and 5 of a spontaneous menstrual cycle, at 07:00 to 09:00, after overnight fasting. Serum levels of follicle-stimulating hormone (FSH), luteinizing hormone (LH), total testosterone, prolactin, sex hormone-binding globulin (SHBG), glucose, insulin, adiponectin and resistin were measured. Results: Serum adiponectin levels were significantly decreased in group A compared with group B and group C. No significant difference existed in adiponectin between group B and group C. Homeostasis Model of Assessment—Insulin Resistance (HOMA-IR) value in group A was found to be significantly higher than group C, but no significant differences were found between group B and group C or between group A and group B. There was no significant difference in serum resistin between all groups, nevertheless the resistin-to-adiponectin (R:A) ratio was significantly decreased in group A compared with groups B and C. In a multiple regression model, BMI, testosterone and insulin resistance were the major determinants of hypoadiponectinemia. However, only BMI was the major determinant of the resistin represented by the R:A ratio. Conclusions: Serum adiponectin levels and the ratio of resistin to adiponectin levels are reduced in obese women with PCOS. These results suggest that, by reducing adiponectin serum level, hyperandrogenemia, together with nutritional status of obesity, might contribute to insulin resistance in the pathogenesis of PCOS.

scholarly journals Evidence that polymorphisms in detoxification genes modulate the susceptibility for sporadic medullary thyroid carcinoma

2012 ◽  
Vol 166 (2) ◽  
pp. 241-245 ◽  
Author(s):  
R B Barbieri ◽  
N E Bufalo ◽  
R Secolin ◽  
A C N Silva ◽  
L V M Assumpção ◽  
...  
Keyword(s):  
Regression Analysis ◽  
Thyroid Cancer ◽  
Stepwise Regression ◽  
Differentiated Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Cell Cycle Control ◽  
Control Group ◽  
Healthy Individuals ◽  
Medullary Thyroid ◽  
Low Penetrance Genes

AimPolymorphic low-penetrance genes have been consistently associated with the susceptibility to a series of human tumors, including differentiated thyroid cancer.MethodsTo determine their role in medullary thyroid cancer (MTC), we used TaqMan SNP method to genotype 47 sporadic MTC (s-MTC) and a control group of 578 healthy individuals for CYP1A2*F, CYP1A1m1, GSTP1, NAT2 and 72TP53. A logistic regression analysis showed that NAT2C/C (OR=3.87; 95% CI=2.11–7.10; P=2.2×10−5) and TP53C/C genotypes (OR=3.87; 95% CI=1.78–6.10; P=2.8×10−4) inheritance increased the risk of s-MTC. A stepwise regression analysis indicated that TP53C/C genotype contributes with 8.07% of the s-MTC risk.ResultsWe were unable to identify any relationship between NAT2 and TP53 polymorphisms suggesting they are independent factors of risk to s-MTC. In addition, there was no association between the investigated genes and clinical or pathological features of aggressiveness of the tumors or the outcome of MTC patients.ConclusionIn conclusion, we demonstrated that detoxification genes and apoptotic and cell cycle control genes are involved in the susceptibility of s-MTC and may modulate the susceptibility to the disease.

Effect of sorafenib in symptomatic metastatic medullary thyroid cancer

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 14065-14065 ◽  
Author(s):  
F. Kober ◽  
M. Hermann ◽  
A. Handler ◽  
G. Krotla
Keyword(s):  
Thyroid Cancer ◽  
Side Effects ◽  
Tyrosine Kinases ◽  
Medullary Thyroid Cancer ◽  
Serum Levels ◽  
Primary Objective ◽  
Medullary Thyroid ◽  
Severe Diarrhea ◽  
Metastatic Lesions ◽  
Octreotide Therapy

14065 Background: RET receptor tyrosin kinase activity plays a major role in medullary thyroid cancer (MTC) tumor growth. Sorafenib is an oral agent that selectively targets RET tyrosine kinases. Methods: 5 patients (pts) with metastatic MTC with excessive elevation of calcitonin(CTN) serum levels entered this pilotstudy. Hypercalcitonemia-related symptoms were present in all pts (3 severe diarrhea, 2 moderate) and metastasis- related symptoms were present in 4 pts (2 severe pain, 2 moderate). All pts had had prior thyreoidectomy and cervical +- mediastinal lymphnode dissection, 4 pts had prior octreotide therapy, 3 prior chemotherapy. Pts received 800 mg or 400 mg (weight < 50 kg) Sorafenib as a starting dose. According to the protocol, the dose was reduced gradually in 200 mg scale when pts revealed therapy induced side effects to avoid worsening of quality of life. Sorafenib has to be administered at least 3 months, the scheduled duration of therapy was 6 months. Physical examination, calcitonin and CEA levels were monitored every 4 weeks, measurable metastatic lesions were controlled by appropriate means 3 and 6 months after starting therapy. Primary objective was to assess the effect on CTN dependent symptoms, second objectives included assessments of tumor response (RECIST) and biochemical response. Results: After 2–3 months CTN decreased to levels >50% of baseline in all pts, to levels >90% in 2 pts. According to that all pts were free of CTN related symptoms after 4 weeks. In 4 pts CEA levels reacted in a similar way. After 6 months controls of metastatic lesions were classified as CR-1 pt, PR-1 pt, NC-3 pts. 2 pts with severe metastasis-related pain were off analgesics after 3 months of treatment. Due to side effects Sorafenib dosage was reduced to 50% of the initial dose in all patients. Interestingly marked TSH - elevations were observed in 3 pts which indicates a direct influence to the hypothalamic-pituary-axis. Conclusion: Sorafenib has to be considered as an effective teatment of symptomatic, metastatic MTC. No significant financial relationships to disclose.

scholarly journals Elevated level of serum carbohydrate antigen 19.9 as predictor of mortality in patients with advanced medullary thyroid cancer

2015 ◽  
Vol 173 (3) ◽  
pp. 297-304 ◽  
Author(s):  
Rossella Elisei ◽  
Loredana Lorusso ◽  
Paolo Piaggi ◽  
Liborio Torregrossa ◽  
Giovanni Pellegrini ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Elevated Level ◽  
Medullary Thyroid Cancer ◽  
Rapid Evolution ◽  
Carbohydrate Antigen ◽  
Control Group ◽  
Medullary Thyroid ◽  
Risk Of Mortality ◽  
Ca 19.9 ◽  
Serum Carbohydrate Antigen

BackgroundMedullary thyroid cancer (MTC) is capable of secreting several proteins, such as calcitonin (Ct), carcinoembryonic antigen (CEA), chromogranin and others. Recently, we observed an aggressive MTC with high levels of serum carbohydrate antigen 19.9 (Ca 19.9) and a rapid evolution to death.ObjectiveThe aim of this study was to evaluate whether high levels of serum Ca 19.9 could be a prognostic factor of death in patients with advanced MTC.Patients and methodsWe measured Ca 19.9, CEA and Ct in 100 advanced structural recurrent/persistent MTC patients and in 100 cured or biochemically affected MTC patients. Clinical and pathological data were also collected.ResultsSixteen percent of the patients with advanced MTC had high levels of Ca 19.9. The group with abnormal Ca 19.9 levels had significantly higher levels of CEA and Ct compared with the group with normal values of Ca 19.9 (P<0.0001 for both Ct and CEA). At variance, all 100 patients in the MTC control group showed normal levels of Ca 19.9. Moreover, among the advanced cases, the Ca 19.9-positive group showed a higher mortality rate than the group with normal levels. A logistic regression analysis demonstrated that an elevated level of Ca 19.9 is a predictor of mortality (OR=3.78,P=0.04), independent from Ct doubling time.ConclusionsThese results demonstrated that an elevated value of serum Ca 19.9 appears to be a predictive factor of poor prognosis in advanced MTC patients and identifies those cases with a higher risk of mortality in the short term.

scholarly journals Medullary thyroid cancer treated with vandetanib: predictors of a longer and durable response

2020 ◽  
Vol 27 (2) ◽  
pp. 97-110 ◽  
Author(s):  
Laura Valerio ◽  
Valeria Bottici ◽  
Antonio Matrone ◽  
Paolo Piaggi ◽  
David Viola ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Kinase Inhibitor ◽  
Performance Status ◽  
Durable Response ◽  
Medullary Thyroid ◽  
Symptomatic Disease ◽  
Younger Age ◽  
Significant Difference

Vandetanib is an important treatment option for advanced metastatic medullary thyroid cancer. The aims of this study were to evaluate the predictors of both a longer response to vandetanib and the outcome. Medical records of 79 medullary thyroid cancer patients treated with vandetanib at our center were analysed. Twenty-five patients were treated for <12 months, 54 were treated for ≥12 months and 24 of these latter were treated for ≥48 months (short-, long- and very long-term). The median progression free survival of the long and very long-term treated patients was significantly longer than in the ZETA trial. When comparing the groups of short - and long-term treated patients the only significant difference was that these latter were less frequently previously treated with a tyrosine kinase inhibitor. However, the long-term treated patients had a younger age, both at diagnosis and enrolment, which was statistically significant in the very long-term treated patients. In the long-term treated group, younger age, enrolment for symptoms and development of adverse events were significantly correlated with a better outcome. The enrolment for symptoms remained the only statistically significant predictor of a good outcome in the very long-term treated patients. In conclusion, early treatment with vandetanib, when patients are younger, with a good ECOG performance status and symptomatic disease, not necessarily progressing for RECIST, seem to be the best predictors of a longer and durable response. Further studies are needed to confirm these results.

scholarly journals Medullary thyroid cancer is associated with high serum vitamin D level and polymorphism of vitamin D receptors

2020 ◽  
Vol 107 (1) ◽  
pp. 120-133
Author(s):  
M Ramezani ◽  
M Mazani ◽  
M Tabatabaei ◽  
A Rahimian ◽  
E Mosaferi ◽  
...  
Keyword(s):  
Vitamin D ◽  
Thyroid Cancer ◽  
Medullary Thyroid Cancer ◽  
Serum Vitamin ◽  
Test Group ◽  
Allelic Frequency ◽  
Control Group ◽  
Medullary Thyroid ◽  
Vitamin D Receptors ◽  
Serum Vitamin D

AbstractBackgroundThyroid cancer is the most common endocrine malignancy. Studies have observed an anti-cancer effect for vitamin D and found that polymorphisms of vitamin D receptors can influence the prevalence of various cancers. The present study investigated the serum level of vitamin D and FokI, BsmI and Tru9I polymorphisms of vitamin D receptors.MethodsForty patients with medullary thyroid cancer and 40 healthy controls were investigated. The genomic DNA of the subjects was extracted using saturated salt/proteinase K and investigated by PCR sequencing. Serum levels of vitamin D were evaluated by ELISA. The results were analyzed in SPSS and GraphPad Prism 5 software.ResultsThe genotypic and allelic frequencies of FokI and BsmI polymorphisms showed no significant differences between test and control groups. For Tru9I polymorphism, Tt genotype and t allelic frequency in the test group were significantly different from those of the control group. Also, we found Tt genotype and t allelic frequency to be significantly associated with medullary thyroid cancer (MTC) type and the agressiveness of the disease. The average serum vitamin D level was 23.32 ng/mL and 18.95 ng/mL for patients and controls, respectively, and the difference between the two groups was statistically significant. Moreover, we found high serum vitamin D level to be associated with t allelic frequency.ConclusionsUnexpectedly, the mean serum vitamin D level of the test group was significantly higher than that of the control group. Tru9I polymorphism was found to be significantly correlated with the prevalence of medullary thyroid carcinoma.

Clinical correlates of thrombodynamics in men with metabolic syndrome: the impact of insulin resistance

2016 ◽  
Vol 62 (5) ◽  
pp. 25-26
Author(s):  
Ivan Y. Pchelin ◽  
Natalia V. Hudiakova ◽  
Alexander N. Shishkin
Keyword(s):  
Insulin Resistance ◽  
Metabolic Syndrome ◽  
Serum Levels ◽  
Control Group ◽  
C Reactive Protein ◽  
Clinical Correlates ◽  
Insulin Resistant ◽  
Reactive Protein ◽  
Significant Difference ◽  
The Impact

Background. Hypercoagulation is one of the cardiovascular risk factors in patients with metabolic syndrome (MS). It results from various factors including hyperhomocysteinemia, endothelial dysfunction, non-enzymatic glycation of proteins etc.The aim of this study was to assess clinical correlates of thrombodynamics in insulin resistant and non insulin resistant men with metabolic syndrome.Methods. We investigated 79 patients with MS diagnosed in accordance with IDF criteria (2009). The main group consisted of 44 men with MS including insulin resistance. The control group consisted of 35 men with MS not including insulin resistance. In addition to routine clinical tests we performed thrombodynamics assay and measured serum levels of asymmetric dimethylarginine (ADMA) and homocysteine. Mann-Whitney U-test and Spearmen’s correlation coefficient (rs) were used for statistical analysis.Results. There was no significant difference between thrombodynamics parameters, ADMA and homocysteine levels between the two groups. In both groups thrombodynamics parameters had no correlations with body mass index, hemoglobin level, platelet count and serum ADMA level. In patients with insulin resistance clot density correlated positively with serum level of C-reactive protein (rs=0.621, p=0.007); average and initial rates of clot growth correlated positively with homocysteine level (rs=0.539, p=0.017, and rs=0.554, p=0.014, respectively). In patients with insulin resistance clot density and rates of clot growth were not interrelated with the above mentioned parameters.Conclusions. The results of the study suggest that insulin resistant men with MS are characterized by clinical correlates between thrombodynamics parameters, homocysteine and C-reactive protein levels while patients without insulin resistance have other, unestablished determinants of clot density and rates of clot growth.

Sign in / Sign up

Export Citation Format

Share Document